Literature DB >> 14978074

Phosphatidylinositol 3-kinase-dependent mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 and NF-kappa B signaling pathways are required for B cell antigen receptor-mediated cyclin D2 induction in mature B cells.

Michael J Piatelli1, Carrie Wardle, Joseph Blois, Cheryl Doughty, Brian R Schram, Thomas L Rothstein, Thomas C Chiles.   

Abstract

Phosphatidylinositol 3-kinase (PI-3K) has been linked to promitogenic responses in splenic B cells following B cell Ag receptor (BCR) cross-linking; however identification of the signaling intermediates that link PI-3K activity to the cell cycle remains incomplete. We show that cyclin D2 induction is blocked by the PI-3K inhibitors wortmannin and LY294002, which coincides with impaired BCR-mediated mitogen-activated protein/extracellular signal-related kinase kinase (MEK)1/2 and p42/44ERK phosphorylation on activation residues. Cyclin D2 induction is virtually absent in B lymphocytes from mice deficient in the class I(A) PI-3K p85alpha regulatory subunit. In contrast to studies with PI-3K inhibitors, which inhibit all classes of PI-3Ks, the p85alpha regulatory subunit is not required for BCR-induced MEK1/2 and p42/44ERK phosphorylation, suggesting the contribution of another PI-3K family members in MEK1/2 and p42/44ERK activation. However, p85alpha(-/-) splenic B cells are defective in BCR-induced IkappaB kinase beta and IkappaBalpha phosphorylation. We demonstrate that NF-kappaB signaling is required for cyclin D2 induction via the BCR in normal B cells, implicating a possible link with the defective IkappaB kinase beta and IkappaBalpha phosphorylation in p85alpha(-/-) splenic B cells and their ability to induce cyclin D2. These results indicate that MEK1/2-p42/44ERK and NF-kappaB pathways link PI-3K activity to Ag receptor-mediated cyclin D2 induction in splenic B cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978074     DOI: 10.4049/jimmunol.172.5.2753

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth.

Authors:  Cheryl A Doughty; Blair F Bleiman; Dean J Wagner; Fay J Dufort; Jennifer M Mataraza; Mary F Roberts; Thomas C Chiles
Journal:  Blood       Date:  2006-01-31       Impact factor: 22.113

2.  Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection.

Authors:  Laurent Verkoczy; Bao Duong; Patrick Skog; Djemel Aït-Azzouzene; Kamal Puri; José Luis Vela; David Nemazee
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

Review 3.  Regulation of B-cell entry into the cell cycle.

Authors:  Sabrina Richards; Chie Watanabe; Lorna Santos; Andrew Craxton; Edward A Clark
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

4.  Rewiring of sIgM-Mediated Intracellular Signaling through the CD180 Toll-like Receptor.

Authors:  Nino Porakishvili; Ketki Vispute; Andrew J Steele; Nadeeka Rajakaruna; Nina Kulikova; Tamar Tsertsvadze; Amit Nathwani; Rajendra N Damle; Edward A Clark; Kanti R Rai; Nicholas Chiorazzi; Peter M Lydyard
Journal:  Mol Med       Date:  2015-01-14       Impact factor: 6.354

Review 5.  Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K.

Authors:  Klaus Okkenhaug; Khaled Ali; Bart Vanhaesebroeck
Journal:  Trends Immunol       Date:  2007-01-05       Impact factor: 16.687

6.  LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation.

Authors:  Keiko Morimoto; Yoshihiro Baba; Hisaaki Shinohara; Sujin Kang; Satoshi Nojima; Tetsuya Kimura; Daisuke Ito; Yuji Yoshida; Yohei Maeda; Hana Sarashina-Kida; Masayuki Nishide; Takashi Hosokawa; Yasuhiro Kato; Yoshitomo Hayama; Yuhei Kinehara; Tatsusada Okuno; Hyota Takamatsu; Toru Hirano; Yoshihito Shima; Masashi Narazaki; Tomohiro Kurosaki; Toshihiko Toyofuku; Atsushi Kumanogoh
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.